Human Genome Sciences CEO
William Haseltine, 57, combines a passion for scientific exploration and a talent for directing researchers toward practical and profitable products. By investigating the genes most relevant to pharmaceutical research, Human Genome Sciences is transforming itself into the world's first genomics-based pharmaceutical behemoth. It already has six drugs in clinical trials, for diseases including lupus, colitis and several chemotherapy- induced ailments. Haseltine's approach to decoding the genome promises to bring biotech's benefits more quickly to patients and shareholders alike.
Next Morris Chang